Published in Circ Cardiovasc Genet on October 11, 2012
Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation (2013) 2.03
Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol (2016) 1.68
Premature coronary heart disease and autosomal dominant hypercholesterolemia: Increased risk in women with LDLR mutations. J Clin Lipidol (2015) 0.76
The panorama of familial hypercholesterolemia in Latin America: a systematic review. J Lipid Res (2016) 0.75
Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia. Am Heart J (2016) 0.75
When it looks like familial hypercholesterolemia...but is not. Circ Cardiovasc Genet (2012) 0.75
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res (2002) 16.02
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet (2003) 11.67
Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2010) 9.18
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest (2003) 4.42
Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci (2007) 3.59
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest (2006) 3.54
Genetic and environmental influences on serum lipid levels in twins. N Engl J Med (1993) 3.43
Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation (1974) 3.29
Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Ann Hum Genet (2008) 2.05
Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab (2009) 1.95
The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet (1991) 1.88
Homozygous familial hypercholesterolemia among French Canadians in Québec Province. Arteriosclerosis (1989) 1.68
Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem (2009) 1.65
Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children. Circulation (2011) 1.65
Experiences with the homozygous cases of familial hypercholesterolemia. A report of 52 patients. Nutr Metab (1973) 1.63
LDLR and ApoB are major genetic causes of autosomal dominant hypercholesterolemia in a Taiwanese population. J Formos Med Assoc (2007) 1.43
Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clin Genet (2007) 1.35
Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin Genet (2010) 1.29
Update on dyslipidemia. J Clin Endocrinol Metab (2007) 1.22
Spectrum of LDL receptor gene mutations in heterozygous familial hypercholesterolemia. Hum Mutat (1997) 1.18
Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol (2008) 1.14
Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem (2009) 1.09
Molecular characterization of Polish patients with familial hypercholesterolemia: novel and recurrent LDLR mutations. J Appl Genet (2010) 1.04
Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells. Atherosclerosis (2008) 1.04
Genetic heterogeneity of autosomal dominant hypercholesterolemia in Mexico. Arch Med Res (2006) 0.99
Familial hypercholesterolaemia--a common genetic disorder in the Afrikaans population. S Afr Med J (1980) 0.98
Update of the Portuguese Familial Hypercholesterolaemia Study. Atherosclerosis (2010) 0.95
Prevalence of familial hypercholesterolemia in Johannesburg Jews. Am J Med Genet (1989) 0.95
Molecular spectrum of autosomal dominant hypercholesterolemia in France. Hum Mutat (2010) 0.95
Low density lipoprotein--receptor (LDL-R) gene mutations among Filipinos with familial hypercholesterolemia. J Atheroscler Thromb (2005) 0.94
Low density lipoprotein receptor (LDLR) gene mutations in Canadian subjects with familial hypercholesterolemia, but not of French descent. Hum Mutat (2001) 0.91
[After the LDL receptor and apolipoprotein B, autosomal dominant hypercholesterolemia reveals its third protagonist: PCSK9]. Ann Endocrinol (Paris) (2007) 0.87
Functional analysis of LDLR promoter and 5' UTR mutations in subjects with clinical diagnosis of familial hypercholesterolemia. Hum Mutat (2011) 0.87
Analysis of sequence variations in low-density lipoprotein receptor gene among Malaysian patients with familial hypercholesterolemia. BMC Med Genet (2011) 0.87
Low-density lipoprotein receptor gene mutations in a Southeast Asian population with familial hypercholesterolemia. Clin Genet (2000) 0.87
Molecular genetic testing for familial hypercholesterolemia in the Netherlands: a stepwise screening strategy enhances the mutation detection rate. Genet Test (2006) 0.86
Corneal arcus, case finding and definition of individual clinical risk in heterozygous familial hypercholesterolaemia. Clin Genet (1998) 0.84
Update of Japanese common LDLR gene mutations and their phenotypes: Mild type mutation L547V might predominate in the Japanese population. Atherosclerosis (2008) 0.83
Apolipoprotein A-I kinetics in heterozygous familial hypercholesterolemia: a stable isotope study. J Lipid Res (1999) 0.83
R3531C mutation in the apolipoprotein B gene is not sufficient to cause hypercholesterolemia. Arterioscler Thromb Vasc Biol (2000) 0.82
Association of heterozygous familial hypercholesterolemia with smaller HDL particle size. Atherosclerosis (2006) 0.82
FH clinical phenotype in Greek patients with LDL-R defective vs. negative mutations. Eur J Clin Invest (2004) 0.82
Serum apolipoproteins in heterozygous familial hypercholesterolemia. Clin Chim Acta (1992) 0.80
Predominance of a 6 bp deletion in exon 2 of the LDL receptor gene in Africans with familial hypercholesterolaemia. J Med Genet (2000) 0.79
Leptin-replacement therapy for lipodystrophy. N Engl J Med (2002) 7.78
LMNA mutations in atypical Werner's syndrome. Lancet (2003) 4.81
Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care (2002) 4.46
Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc (2003) 4.42
Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol (2013) 3.41
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol (2009) 3.30
The lipodystrophy protein seipin is found at endoplasmic reticulum lipid droplet junctions and is important for droplet morphology. Proc Natl Acad Sci U S A (2007) 3.11
AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet (2002) 3.09
Influence of body fat content and distribution on variation in metabolic risk. J Clin Endocrinol Metab (2006) 2.73
Association of urinary pH with body weight in nephrolithiasis. Kidney Int (2004) 2.67
Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum Mol Genet (2003) 2.36
Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension (2012) 2.23
Autophagy genes protect against Salmonella typhimurium infection and mediate insulin signaling-regulated pathogen resistance. Proc Natl Acad Sci U S A (2009) 2.21
Genetic disorders of adipose tissue development, differentiation, and death. Annu Rev Genomics Hum Genet (2006) 2.17
PSMB8 encoding the β5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am J Hum Genet (2010) 2.05
Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol (2007) 2.02
Association of Hyperchloremia With Hospital Mortality in Critically Ill Septic Patients. Crit Care Med (2015) 1.93
Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care (2003) 1.91
Ras regulates assembly of mitogenic signalling complexes through the effector protein IMP. Nature (2004) 1.87
Echocardiographic indices do not reliably track changes in left-sided filling pressure in healthy subjects or patients with heart failure with preserved ejection fraction. Circ Cardiovasc Imaging (2011) 1.86
Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Mol Med (2009) 1.80
Review: long-term impact of bariatric surgery on body weight, comorbidities, and nutritional status. J Clin Endocrinol Metab (2006) 1.79
Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy. Cell Metab (2009) 1.79
Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int (2002) 1.78
Nutrition principles and recommendations in diabetes. Diabetes Care (2004) 1.78
Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab (2002) 1.78
Metabolic syndrome and the risk of calcium stones. Nephrol Dial Transplant (2012) 1.71
Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction. Eur J Heart Fail (2011) 1.69
β-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care (2012) 1.66
Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. J Am Soc Nephrol (2006) 1.66
Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem (2009) 1.65
Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J Clin Endocrinol Metab (2003) 1.65
A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab (2002) 1.61
Open-cell versus closed-cell stent design differences in blood flow velocities after carotid stenting. J Vasc Surg (2009) 1.58
Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine (Baltimore) (2003) 1.58
Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore) (2004) 1.55
Hypercalciuria associated with high dietary protein intake is not due to acid load. J Clin Endocrinol Metab (2011) 1.54
Body fat content and distribution and urinary risk factors for nephrolithiasis. Clin J Am Soc Nephrol (2013) 1.51
Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol (2009) 1.50
Effect of a culturally sensitive cholesterol lowering diet program on lipid and lipoproteins, body weight, nutrient intakes, and quality of life in patients with systemic lupus erythematosus. J Rheumatol (2002) 1.49
Defining hypercalciuria in nephrolithiasis. Kidney Int (2011) 1.44
Genetic basis of lipodystrophies and management of metabolic complications. Annu Rev Med (2006) 1.44
Laminopathies: multisystem dystrophy syndromes. Mol Genet Metab (2005) 1.44
Noninvasive quantification of pancreatic fat in humans. J Clin Endocrinol Metab (2009) 1.44
ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes. Diabetes (2005) 1.43
Renal ammonium excretion after an acute acid load: blunted response in uric acid stone formers but not in patients with type 2 diabetes. Am J Physiol Renal Physiol (2013) 1.40
Stimulated growth hormone concentrations in obese pediatric patients with mild and severe insulin resistance: a pilot study. J Pediatr Endocrinol Metab (2010) 1.39
Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? Diabetes Care (2009) 1.38
Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab (2002) 1.38
Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia. J Clin Oncol (2009) 1.36
Genetic and phenotypic heterogeneity in patients with mandibuloacral dysplasia-associated lipodystrophy. J Clin Endocrinol Metab (2003) 1.33
Congenital generalized lipodystrophy: significance of triglyceride biosynthetic pathways. Trends Endocrinol Metab (2003) 1.31
Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. J Clin Endocrinol Metab (2003) 1.30
Seipin: a mysterious protein. Trends Mol Med (2004) 1.27
Functional sympatholysis is impaired in hypertensive humans. J Physiol (2011) 1.25
Lipodystrophy: lessons in lipid and energy metabolism. Curr Opin Lipidol (2006) 1.25
Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology (2008) 1.24
Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med (2003) 1.21
Enzymatic activity of naturally occurring 1-acylglycerol-3-phosphate-O-acyltransferase 2 mutants associated with congenital generalized lipodystrophy. Biochem Biophys Res Commun (2005) 1.20
Body fat distribution and metabolic derangements in patients with familial partial lipodystrophy associated with mandibuloacral dysplasia. J Clin Endocrinol Metab (2002) 1.19
Hepatic steatosis, insulin resistance, and adipose tissue disorders. J Clin Endocrinol Metab (2002) 1.19
Rapid Communication: relative effect of urinary calcium and oxalate on saturation of calcium oxalate. Kidney Int (2004) 1.18
Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel PTRF mutations. Am J Med Genet A (2010) 1.15
Ethnic differences in the frequency of ENPP1/PC1 121Q genetic variant in the Dallas Heart Study cohort. J Diabetes Complications (2007) 1.15
Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. J Clin Invest (2012) 1.14
Effect of high-dose alpha-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease. Am J Clin Nutr (2007) 1.14
Predictors of fracture risk and bone mineral density in men with prostate cancer on androgen deprivation therapy. J Osteoporos (2011) 1.10
CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Am J Clin Pathol (2008) 1.10
Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab (2002) 1.10
Functional characterization of human 1-acylglycerol-3-phosphate-O-acyltransferase isoform 9: cloning, tissue distribution, gene structure, and enzymatic activity. J Endocrinol (2007) 1.09
Functional characterization of human 1-acylglycerol-3-phosphate acyltransferase isoform 8: cloning, tissue distribution, gene structure, and enzymatic activity. Arch Biochem Biophys (2006) 1.08
Effect of dietary calcium on stone forming propensity. J Urol (2003) 1.08
A novel syndrome of mandibular hypoplasia, deafness, and progeroid features associated with lipodystrophy, undescended testes, and male hypogonadism. J Clin Endocrinol Metab (2010) 1.07
Deletion of GPIHBP1 causing severe chylomicronemia. J Inherit Metab Dis (2011) 1.06
Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. J Clin Endocrinol Metab (2013) 1.04
Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism. J Clin Endocrinol Metab (2010) 1.04
Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J Clin Endocrinol Metab (2011) 1.04
Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab (2009) 1.03
The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract (2013) 1.02
Inherited lipodystrophies and hypertriglyceridemia. Curr Opin Lipidol (2009) 1.01
Human 1-acylglycerol-3-phosphate O-acyltransferase isoforms 1 and 2: biochemical characterization and inability to rescue hepatic steatosis in Agpat2(-/-) gene lipodystrophic mice. J Biol Chem (2011) 1.01
Focal segmental glomerulosclerosis in patients with mandibuloacral dysplasia owing to ZMPSTE24 deficiency. J Investig Med (2006) 1.00
Variable contributions of fat content and distribution to metabolic syndrome risk factors. Metab Syndr Relat Disord (2008) 0.99
Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care (2003) 0.99
High-volume exercise program in obese bariatric surgery patients: a randomized, controlled trial. Obesity (Silver Spring) (2011) 0.98
Functional characterization of the human 1-acylglycerol-3-phosphate-O-acyltransferase isoform 10/glycerol-3-phosphate acyltransferase isoform 3. J Mol Endocrinol (2009) 0.98
Early onset mandibuloacral dysplasia due to compound heterozygous mutations in ZMPSTE24. Am J Med Genet A (2010) 0.98
Ethnic difference in sex gap in high-density lipoprotein cholesterol between Asian Indians and Whites. J Investig Med (2008) 0.98
Comparison of type 1, type 2, and atypical ketosis-prone diabetes at 4 years of diabetes duration. J Diabetes Complications (2006) 0.97
Cardiac steatosis and left ventricular hypertrophy in patients with generalized lipodystrophy as determined by magnetic resonance spectroscopy and imaging. Am J Cardiol (2013) 0.97
Novel subtype of congenital generalized lipodystrophy associated with muscular weakness and cervical spine instability. Am J Med Genet A (2008) 0.97
Severe mandibuloacral dysplasia-associated lipodystrophy and progeria in a young girl with a novel homozygous Arg527Cys LMNA mutation. J Clin Endocrinol Metab (2008) 0.97
Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. J Investig Med (2007) 0.97
Caveolin-1: a new locus for human lipodystrophy. J Clin Endocrinol Metab (2008) 0.96
Risk factors for diabetes in familial partial lipodystrophy, Dunnigan variety. Diabetes Care (2003) 0.96
Mislocalization of prelamin A Tyr646Phe mutant to the nuclear pore complex in human embryonic kidney 293 cells. Biochem Biophys Res Commun (2007) 0.95
Acute post-gastric reduction surgery (APGARS) neuropathy. Obes Surg (2004) 0.94